Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Jenny Saub"'
Autor:
Jennifer Edelmann, Karlheinz Holzmann, Eugen Tausch, Emily A. Saunderson, Billy M. C. Jebaraj, Daniela Steinbrecher, Anna Dolnik, Tamara J. Blätte, Dan A. Landau, Jenny Saub, Sven Estenfelder, Stefan Ibach, Florence Cymbalista, Veronique Leblond, Alain Delmer, Jasmin Bahlo, Sandra Robrecht, Kirsten Fischer, Valentin Goede, Lars Bullinger, Catherine J. Wu, Daniel Mertens, Gabriella Ficz, John G. Gribben, Michael Hallek, Hartmut Döhner, Stephan Stilgenbauer
Publikováno v:
Haematologica, Vol 105, Iss 5 (2020)
To identify genomic alterations contributing to the pathogenesis of high-risk chronic lymphocytic leukemia (CLL) beyond the well-established role of TP53 aberrations, we comprehensively analyzed 75 relapsed/refractory and 71 treatment-naïve high-ris
Externí odkaz:
https://doaj.org/article/b6616ac47caa446b810bf72999b7a258
Autor:
Eugen Tausch, Alain Delmer, Sandra Robrecht, Karlheinz Holzmann, Florence Cymbalista, Valentin Goede, Stephan Stilgenbauer, Tamara J. Blätte, Jenny Saub, Gabriella Ficz, Daniela Steinbrecher, Anna Dolnik, Hartmut Döhner, Billy Michael Chelliah Jebaraj, Stefan Ibach, Véronique Leblond, Dan A. Landau, John G. Gribben, Daniel Mertens, Jennifer Edelmann, Emily A. Saunderson, Catherine J. Wu, Sven Estenfelder, Kirsten Fischer, Lars Bullinger, Jasmin Bahlo, Michael Hallek
Publikováno v:
Haematologica
To identify genomic alterations contributing to the pathogenesis of high-risk chronic lymphocytic leukemia (CLL) beyond the well-established role of TP53 aberrations, we comprehensively analyzed 75 relapsed/refractory and 71 treatment-naive high-risk
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a9c99c1b2b31855e80f3cb00f17fa013
http://edoc.mdc-berlin.de/22667/2/22667suppl.zip
http://edoc.mdc-berlin.de/22667/2/22667suppl.zip
Autor:
Urs Schanz, Angela Fischer, Jenny Saub, Sergio Cogliatti, Karin Hohloch, Sara Bastian, Barbara Padberg, Ulrich Mey
Publikováno v:
Hematological Oncology. 36:370-371
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b43a47df954d2a7631adca91b19113ca
https://doi.org/10.1002/hon.2464
https://doi.org/10.1002/hon.2464
Autor:
Stephan Stilgenbauer, Hartmut Döhner, Eugen Tausch, Jenny Saub, Karlheinz Holzmann, John G. Gribben, Véronique Leblond, Johannes Bloehdorn, Daniel Mertens, Jennifer Edelmann, Alain Delmer, Thorsten Zenz, Michael Hallek, Stefan Ibach, Florence Cymbalista
Publikováno v:
Blood. 124:3288-3288
Introduction: “Ultra high-risk” chronic lymphocytic leukemia (CLL) can be defined by TP53 loss and/or mutation, and refractory or early relapsing disease after intense chemo(immuno)therapy. Since its pathogenic mechanisms are not fully understood
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4a91672cc50ff5132aae8a0e739f43f3
https://doi.org/10.1182/blood.v124.21.3288.3288
https://doi.org/10.1182/blood.v124.21.3288.3288